STUDresearch · Peptide
Rusfertide
Also known as
MIMRYLO · PTG-300 · hepcidin mimetic · rusfertide PV
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
Labeled SubQ / not a gray GLP vial
Hormone modulators
Systemic hepcidin-mimetic peptide approved for polycythemia vera erythrocytosis.
What people say
Rusfertide (MIMRYLO) is a hepcidin-mimetic peptide approved for PV erythrocytosis. It is not a gray GLP or gym peptide.
Doses people talk about
An approval headline is not a physique dose.
How it may feel
No physique self-use feel curve was found.
Labeled starting dose19 mg SC once weekly
VERIFY/label start; titrated for hematocrit, not a physique protocol.
Labeled weekly range9.5–108 mg weekly
Public label range. Hematology, not a DIY conversion.
Half-life & effect duration
- Half-life in the body
- Half-lifeNo settled estimate
- Felt duration people report
- Felt durationNo consistent physique self-use timeline reported
Cycles people discuss
Public clocks are disease-program follow-up, including a VERIFY weeks 20–32 window, not a cut.
Timing
No inspected DIY half-life table; do not paste GLP weekly lore here.
Stacks
2026 X compares the approval to gray GLP shops; that is not a combo protocol.
Watch for
Not a fat-loss peptide.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No inspected public DIY-vial half-life table for rusfertide.
Approval and VERIFY reporting are disease-program clocks, not a gray-vial PK chart.
Label/trial material is not a consumer peptide PK study.
- FDA — Mimrylo (rusfertide) approval for polycythemia vera (2026-08-28) (opens in a new tab)Approved 2026-08-28 for erythrocytosis in adults with polycythemia vera; VERIFY started at 19 mg SC weekly, titrated to keep hematocrit <45%; 76.9% vs 32.9% required no phlebotomy weeks 20–32.Secondary public reporting of an approval package; not a physique trial and not a gray-vial identity check. Confirm current label text on the official FDA page.
Felt duration people report
No physique self-use feel curve was identified.
Talk is approval headlines, not gym diaries.
Disease-program reports are not n=1 physique logs.
- FDA — Mimrylo (rusfertide) approval for polycythemia vera (2026-08-28) (opens in a new tab)Approved 2026-08-28 for erythrocytosis in adults with polycythemia vera; VERIFY started at 19 mg SC weekly, titrated to keep hematocrit <45%; 76.9% vs 32.9% required no phlebotomy weeks 20–32.Secondary public reporting of an approval package; not a physique trial and not a gray-vial identity check. Confirm current label text on the official FDA page.
What people say
- Community use of the headline: “See, peptides can be real medicine.” Not a physique log. forum
- No gym n=1 album. forum
- VERIFY Phase 3: 76.9% hit the defined clinical response in weeks 20–32 in the approval talk people paste. Disease trial. trial
- FDA approval 2026-08-28 for erythrocytosis in adults with polycythemia vera — first approved hepcidin-mimetic in that story. trial
Doses people talk about
- No public DIY gym milligrams. forum
- Community posts repeat “approved peptide” more than a milligram ladder. Follow the label, not a forum conversion. forum
- VERIFY / labeled start: 19 mg SC once weekly, titrated to keep hematocrit below 45%. Hematology, not a gym chart. trial
- Labeled weekly range: 9.5–108 mg once weekly in the public label talk. Follow the label, not a forum conversion. trial
- Framing: Labeled / trial hematology dosing. Not a research-peptide chart. trial
How it may feel
- Now: Approval-headline weeks on peptide Twitter. forum
- If someone treats it like a GLP: that is identity confusion. forum
- Clinic clock: labeled hematology follow-up, not a weekday pump. trial
- Stop: disease-program decisions, not a forum PCT. trial
Cycles people discuss
- Not a GLP titration. forum
- Disease treatment is ongoing care, not an 8-week blast. trial
- VERIFY reported a weeks 20–32 response window — a trial epoch, not a cut. trial
Timing
- Do not paste GLP weekly lore onto a hepcidin mimetic. forum
- No inspected public DIY-vial half-life table. trial
- Clinic timing is labeled hematology follow-up. trial
More on what it is
- Why people talk about it: September 2026 X briefs used the approval as “peptides aren’t only Ozempic.” That is a real-drug headline next to gray GLP shops. forum
- Not a RUO weight-loss vial. forum
- What it is: A hepcidin-mimetic peptide (PTG-300). 2026 brand people paste: MIMRYLO (rusfertide). It tells iron handling to slow down so blood is less thick. trial
- How it works (plain): Hepcidin is the iron-gate hormone. A mimetic reduces available iron for extra red-cell making in PV. Not an appetite peptide. trial
- Not a cut drug. PV erythrocytosis is a hematology job. trial
Stacks
- Not stacked with reta in a kitchen. Approval talk is the comparison, not a combo protocol. forum
- Vs gray GLP shops is the 2026 X one-liner. forum
- Hematology care is the actual context. trial
Storage notes
- Approved / clinic product, not BAC-water culture. forum
Watch for
- Not a fat-loss peptide. forum
- Gray listings with this name are identity risk. forum
- Hematology AE tables belong on the label, not a forum SOP. trial
- Iron / red-cell biology is the point — that is a clinician job. trial
Evidence mix
Mixed trial + community tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.